All In Biotech

Drug Trial Radar · NCT01510860

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

Double-blind, Double-dummy, Randomised, Crossover, Multicentre Phase IV Clinical Study Comparing the Effect of Ursofalk 500 mg Tablets od Versus Ursofalk 250 mg Capsules od on Liver Enzymes in the Treatment of Primary Biliary Cirrhosis

Last checked: Nov 20, 2026Latest source record: May 7, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

65

Actual

Start

Nov 2008

Primary completion

Jul 2010

Study completion Jul 2010

Sponsor

Lead sponsor
Dr. Falk Pharma GmbHIndustry
Sponsor type
Industry
First posted
Jan 18, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of Ursofalk 500 mg tablets versus Ursofalk 500 mg capsules in the treatment of Primary Biliary Cirrhosis (PBC).

Conditions

  • Primary Biliary Cirrhosis

Interventions

  • UDCA (Ursodeoxycholic acid)Drug

    250 mg

  • UDCA (Ursodeoxycholic acid)Drug

    500 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of liver enzymes between baseline and the end of the treatment-period with Ursofalk 250 mg capsules and the end of treatment-period with Ursofalk 500 mg tablets.Time frame: Between baseline and week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Klinikum Grosshadern

    Munich, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.